Hong Liu‐Seifert

5.8k total citations · 1 hit paper
53 papers, 3.6k citations indexed

About

Hong Liu‐Seifert is a scholar working on Psychiatry and Mental health, Physiology and Pharmacology. According to data from OpenAlex, Hong Liu‐Seifert has authored 53 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Psychiatry and Mental health, 18 papers in Physiology and 13 papers in Pharmacology. Recurrent topics in Hong Liu‐Seifert's work include Schizophrenia research and treatment (20 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Alzheimer's disease research and treatments (13 papers). Hong Liu‐Seifert is often cited by papers focused on Schizophrenia research and treatment (20 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Alzheimer's disease research and treatments (13 papers). Hong Liu‐Seifert collaborates with scholars based in United States, Canada and United Kingdom. Hong Liu‐Seifert's co-authors include Eric Siemers, Richard C. Mohs, Bruce J. Kinon, Rachelle S. Doody, Paul Aisen, Rema Raman, Takeshi Iwatsubo, Bruno Vellas, Ronald G. Thomas and Xiaoying Sun and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Hong Liu‐Seifert

52 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

2014 1.2k citations Rachelle S. Doody, Ronald G. Thomas et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Hong Liu‐Seifert

Since Specialization

Citations

This map shows the geographic impact of Hong Liu‐Seifert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hong Liu‐Seifert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hong Liu‐Seifert more than expected).

Fields of papers citing papers by Hong Liu‐Seifert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hong Liu‐Seifert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hong Liu‐Seifert. The network helps show where Hong Liu‐Seifert may publish in the future.

Co-authorship network of co-authors of Hong Liu‐Seifert

This figure shows the co-authorship network connecting the top 25 collaborators of Hong Liu‐Seifert. A scholar is included among the top collaborators of Hong Liu‐Seifert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hong Liu‐Seifert. Hong Liu‐Seifert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial 2025 ·European Heart Journal Open ·Mamas Mamas, Harold Bays, Rui Li, (unknown), Tracy Irani, Çağrı Şenyücel, Julia P. Dunn, Hong Liu‐Seifert	0
2	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial 2019 ·Annals of the Rheumatic Diseases ·Philip J. Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu‐Seifert, Paul Emery, Sreekumar Pillai, Philip Helliwell	208
3	Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer's Disease in EXPEDITION 3 2018 ·The Journal of Prevention of Alzheimer s Disease ·Hong Liu‐Seifert, Eric Siemers, Kristina Sundell, (unknown), Jeffrey L. Cummings, Richard C. Mohs, Paul Aisen	10
4	CORRELATION BETWEEN COGNITION AND FUNCTION ACROSS THE SPECTRUM OF ALZHEIMER’S DISEASE 2016 ·The Journal of Prevention of Alzheimer s Disease ·Hong Liu‐Seifert, Eric Siemers, Katherine J. Selzler, Kristina Sundell, Paul Aisen, Jorden A. Cummings, Joel Raskin, Richard C. Mohs	15
5	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease 2015 ·Journal of Alzheimer s Disease ·Hong Liu‐Seifert, (unknown), Eric Siemers, Karen Price, Baoguang Han, Katherine J. Selzler, David Henley, Karen Sundell, Paul Aisen, Jeffrey L. Cummings, Joel Raskin, Richard C. Mohs	62
6	Delayed-Start Analyses of Solanezumab Phase 3 Studies in Mild Alzheimer’s Disease (P7.108) 2015 ·Neurology ·Hong Liu‐Seifert, Scott W. Andersen, Karen C. Holdridge, Eric Siemers	2
7	Alzheimer’s disease progression by geographical region in a clinical trial setting 2015 ·Alzheimer s Research & Therapy ·David Henley, Sherie A. Dowsett, Yunfei Chen, Hong Liu‐Seifert, Joshua D. Grill, Rachelle S. Doody, Paul Aisen, Rema Raman, David S. Miller, Ann Marie Hake, Jeffrey L. Cummings	23
8	Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease breakdown → 2014 ·New England Journal of Medicine ·Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow, Takeshi Iwatsubo, Bruno Vellas, Steven Joffe, Karl Kieburtz, Rema Raman, Xiaoying Sun, Paul Aisen, Eric Siemers, Hong Liu‐Seifert, Richard C. Mohs	1205
9	Bone Loss Associated with Hyperprolactinemia in Patients with Schizophrenia 2013 ·Clinical Schizophrenia & Related Psychoses ·Bruce J. Kinon, Hong Liu‐Seifert, Virginia L. Stauffer, Jayanthi Jacob	32
10	Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia 2011 ·Comprehensive Psychiatry ·Hong Liu‐Seifert, Olawale Osuntokun, Peter D. Feldman	32
11	Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics 2011 ·BMC Psychiatry ·Hong Liu‐Seifert, Haya Ascher‐Svanum, Olawale Osuntokun, (unknown), Juan Carlos Gómez	10
12	Patient perspectives on antipsychotic treatments and their association with clinical outcomes 2010 ·SHILAP Revista de lepidopterología ·Hong Liu‐Seifert, Olawale Osuntokun, Jenna L. Godfrey, et al.	4
13	A Double‐blind, Randomized, Placebo‐controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the Knee 2010 ·Pain Practice ·Amy S. Chappell, D. Desaiah, Hong Liu‐Seifert, Shuyu Zhang, Vladimir Skljarevski, (unknown), Jacques P. Brown	172
14	Predictors of premature discontinuation of treatment in multiple disease states 2009 ·Patient Preference and Adherence ·(unknown), Hong Liu‐Seifert, (unknown)	25
15	Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone 2009 ·Neuropsychiatric Disease and Treatment ·Hong Liu‐Seifert	37
16	Medication Nonadherence and Treatment Outcome in Patients With Schizophrenia or Schizoaffective Disorder With Suboptimal Prior Response 2009 ·The Journal of Clinical Psychiatry ·Jean-Pierre Lindenmayer, Hong Liu‐Seifert, Pandurang M. Kulkarni, Bruce J. Kinon, Virginia L. Stauffer, Sara Edwards, Lei Chen, David Adams, Haya Ascher‐Svanum, P.F. Buckley, Leslie Citrome, Jan Volavka	131
17	All-Cause Treatment Discontinuation in Schizophrenia During Treatment With Olanzapine Relative to Other Antipsychotics 2007 ·Journal of Clinical Psychopharmacology ·Charles M. Beasley, Virginia L. Stauffer, Hong Liu‐Seifert, Cindy C. Taylor, Eduardo Dunayevich, John M. Davis	35
18	Differential Rates of Treatment Discontinuation in Clinical Trials as a Measure of Treatment Effectiveness for Olanzapine and Comparator Atypical Antipsychotics for Schizophrenia 2006 ·Journal of Clinical Psychopharmacology ·Bruce J. Kinon, Hong Liu‐Seifert, David Adams, Leslie Citrome	28
19	Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs 2005 ·BMC Medicine ·Hong Liu‐Seifert, David H. Adams, Bruce J. Kinon	120
20	Longitudinal Effect of Olanzapine on Fasting Serum Lipids: A Randomized, Prospective, 4‐Month Study 2004 ·Annals of the New York Academy of Sciences ·Bruce J. Kinon, Hong Liu‐Seifert, Jonna Ahl, Saeeduddin Ahmed, Robert W. Baker	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact